<DOC>
	<DOC>NCT01746732</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of evacetrapib on oral contraceptives (Ortho-CyclenÂ®) when given to healthy female participants. The amount of female hormones found in the blood will be measured and compared when taken alone and when taken with evaceptrapib. Each woman will participate in two study periods. Information about any side effects that may occur will also be collected.</brief_summary>
	<brief_title>A Study of Evacetrapib in Healthy Female Participants</brief_title>
	<detailed_description />
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Are premenopausal females, and who are healthy as determined by medical history and physical examination Have a body mass index of 18 to 30 kilograms per square meter (kg/m^2) Have known allergies to evacetrapib and OrthoCyclen (ethinyl estradiol and norgestimate), related compounds or any components of the formulation Have a clinically significant abnormality in the 12lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study Regularly use known drugs of abuse and/or show positive findings on urinary drug screening Have taken injectable contraceptives within 12 months prior to the first dose of the leadin period or topical controlled delivery contraceptives (patch) for 3 months prior to the first dose of the leadin period Use of any tobacco or nicotinecontaining products within 6 months prior to the leadin phase and during the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>